CASE CCC IN THE NEWS
Rising Trend in Genome Mapping Delivers Targeted Breast Cancer Treatment
Newswise - Oct 7, 2013
By studying the genetic makeup of breast cancer patients, doctors are taking the next steps forward in delivering more personalized care to patients...Case Comprehensive Cancer Center member Dr. [Lyndsay] Harris and her team are currently conducting a whole genome sequencing study to examine what changes in the tumor are unique to a breast cancer patient. The anticipated outcome is to determine who will benefit most from certain drug therapies and to use that information to create a personalized treatment plan for each patient involved.
New Research Shows PET Imaging Effective in Predicting Lung Cancer Outcomes
EurekAlert - Oct 7, 2013
Advanced imaging with Positron Emission Tomography (PET) scan shows great promise in predicting which patients with inoperable lung cancer have more aggressive tumors and need additional treatment following standard chemotherapy/radiation therapy, according to new research recently published online in the Journal of Clinical Oncology. The multi-site trial, led by study author and principal investigator Mitch Machtay, MD, University Hospitals Case Medical Center Seidman Cancer Center and the Case Comprehensive Cancer Center in Cleveland, enrolled 250 patients at 60 cancer centers around the country. The National Cancer Institute-funded trial, led by the American College of Radiology Imaging Network (ACRIN) in collaboration with Radiation Therapy Oncology Group (RTOG), enrolled 250 patients at 60 cancer centers around the country.
Ben Venue Closing Adds to Doxil concerns
Crain's Business Cleveland - Oct 6, 2013
It may be a while before ovarian cancer patients here and around the world have the option of being treated with Doxil. Ben Venue Laboratories – the only company in the world that has been approved to make the popular cancer drug – announced last week it would shut down all production by the end of the year...The availability of a generic takes a lot of the sting out of the Doxil shortage, according to Case Comprehensive Cancer Center member Steven Waggoner, division chief of gynecological oncology at University Hospitals Case Medical Center. Even so, UH still uses a lot of Doxil. If an ovarian cancer patient at UH still needs treatment after undergoing surgery and chemotherapy with a different drug, they'll almost always go on Doxil, Lipodox or the generic drug.
Hospitals Maintain Patient Care During Shutdown
WKYC - Oct 4, 2013
"It has to reflect reality and at some level the title was more intense than the facts in terms of what we're able to do," says Dr. John Letterio, Division Chief, Pediatric Hematology and Oncology at University Hospitals Rainbow Babies & Children's Hospital and member of the Case Comprehensive Cancer Center. Locally, our doctors, those at the Cleveland Clinic, University Hospitals, MetroHealth Medical, Case Western, say they are still hard at work, providing care to every patient and everyone currently enrolled in clinical trials.
"Angelina Jolie Effect" Leads To Greater Breast Cancer Awareness And Rise In Unnecessary Surgeries
The Inquisitr - Oct 3, 2013
"For a woman with a gene mutation or a family history, the surgery makes sense," said Dr. Julian Kim. "For most other women who are opting to have it, it is very controversial." Kim, the chief of oncologic surgery at the UH Seidman Cancer Center and member of the Case Comprehensive Cancer Center in Cleveland, told ABC News that there is no evidence to support the idea that removing both breasts after a diagnosis of breast cancer increases survival rate.
The Cutting Edge: Three Cleveland Medical Innovations Bound for Great Things
Freshwater - Oct 3, 2013
In Cleveland, researchers at the Cleveland Clinic are working with medical manufacturers on treatments and technologies that can blast a brain tumor with a laser, detect a concussion using an iPad, and test for prostate cancer by way of genetics...When a man is diagnosed with prostate cancer, the first question he likely will ask is, "How soon can I be treated?" That query can be misleading as treatment is not always the answer, particularly for low-risk cases, explains Dr. Eric Klein, chairman of the Clinic's Glickman Urological and Kidney Institute...Recent years have seen Cleveland Clinic neurosurgeons pursue cutting-edge brain tumor surgery technology. An innovation called NeuroBlate takes "cutting" out of the equation, instead using a concentrated laser that destroys cancerous cells while sparing healthy tissue. "It literally cooks the tumor from inside out," says Dr. Gene Barnett, director of the hospital system's brain tumor and neuro-oncology center...
Big Breast Cancer Breakthroughs Of 2013
Huffington Post - Oct 1, 2013
For women with small ER-positive tumors – about two-thirds of breast cancer patients, says Holly Pederson, MD, a medical breast specialist at the Cleveland Clinic and member of the Case Comprehensive Cancer Center – studies have shown that undergoing one high dose of radiation during a lumpectomy is as effective as six weeks of postsurgical radiation. Plus, there's less risk of harming healthy lung and heart tissue.
Drug Used in Blood Disorders May Kill Brain Tumors: Discoveries
The Plain Dealer - Oct 1, 2013
A drug used to treat blood disorders was successful at destroying human brain tumors implanted in mice in experiments performed at Johns Hopkins University...Case Comprehensive Cancer Center member Dr. Andrew Sloan, a University Hospitals neurosurgeon and associate professor of neurosurgery at Case Western Reserve University, agreed the research is "really interesting and exciting and very good work." Yet Sloan, who was not involved with the work, cautioned that it's still very early to make many conclusions about its future applications in human patients.
New Imaging Test for Multiple Sclerosis Developed at Case Could Help Speed Up New Treatments: Discoveries
The Plain Dealer - Sept 24, 2013
"This is a highly desired technique in the medical community," said Yanming Wang, senior author of the paper describing their findings published Monday in the journal Annals of Neurology, and associate professor of radiology and member of the Case Comprehensive Cancer Center. "[Drug companies] have myelin-repairing drugs in development but no way to measure their effectiveness in a quantitative way. This imaging technique could allow them to do that."
Signal Gradients in 3-D Guide Stem Cell Behavior
Phys.Org - Sept 18
Ultimately, one of their goals is to engineer systems to manipulate stem cells to repair or replace damaged tissues and organs. "If we can control the spatial presentation of signals, we may be able to have more control over cell behavior and enhance the rate and quality of tissue formation," said Case Comprehensive Cancer Center member Eben Alsberg, an associate professor of biomedical engineering and orthopaedic surgery at Case Western Reserve and senior author of the research.
MARK YOUR CALENDARS
New Treatment Paradigms for Melanoma: A Case-based Discussion
Registration is open for New Treatment Paradigms for Melanoma: A Case-based Discussion, presented by the Case Comprehensive Cancer Center on Friday, October 18 at the Holiday Inn-Cleveland South. This conference is intended to provide melanoma caregivers a case-driven overview of current melanoma treatment paradigms. Case CCC faculty will discuss multidisciplinary approaches to the management of early and late stage melanoma.
The conference will cover the integration of new diagnostic and treatment technologies in care of the melanoma patient. In addition, the role of new targeted and immune therapies in the melanoma treatment as well as management of associated novel toxicities will be reviewed. A case-based discussion format will provide the opportunity audience interaction with the course faculty. CME credit is available.
Graft-versus-Host Disease (GvHD) National Symposium
Registration today the Graft-versus-Host Disease (GvHD) National Symposium, Friday, November 1 at the Embassy Suites Cleveland. This conference is intended to raise awareness about the signs and symptoms of GvHD, review cutting edge approaches to prevention and treatment, and highlight and promote research to further our understanding of its cause. The symposium will have two tracks: a scientifically rigorous one for physicians and practitioners, and a survivor track that will focus on challenges faced by BMT recipients and their families. CME credit is available.
Doris Duke Clinical Scientist Development Award
The Doris Duke Clinical Scientist Development Award provides grants to junior physician scientists to facilitate their transition to independent clinical research careers. Pre-proposals are being sought from junior physician-scientist faculty conducting clinical research in any disease area. It is recommended that applicants have significant research experience and strong publication records consistent with the assistant professor rank. This award does not require institutional nomination in 2014.
Pre-proposal Deadline: October 31
Application Deadline: February 25, 2014
GI SPORE Scholars Training Program
The CWRU GI Specialized Program of Research Excellence (SPORE) will fund two new Research Scholars in the next academic year, 2014-2015. This program is designed to support research training leading to independent careers in translational GI Cancer research. Awardees are expected to devote 70% effort to research and training, will conduct a mentored research program in the laboratory or program of one of the SPORE Investigators and have an assigned mentoring team. Applicants must be US citizens and have a faculty appointment at the time the scholarship begins or be in the senior year of a training program with a department commitment to a faculty appointment during the first scholarship year.
Deadline: October 31